Sanofi and Regeneron Pharmaceuticals Inc. are gearing up to submit their PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC), a new, larger indication that would take the drug into the more competitive immuno-oncology market.
Sanofi/Regeneron Ready To Forge Ahead With Libtayo Filings In NSCLC
Cemiplimab was a latecomer to the PD-1/L1 class, but a Phase III success in lung cancer will bring it to the main stage for immuno-oncology.
More from Clinical Trials
More from R&D
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.